Why Puma Biotechnology (PBYI) Stock Is Plunging Today

NEW YORK (TheStreet) -- Puma Biotechnology  (PBYI) plunged Monday after GlaxoSmithKline  (GSK) announced its drug Tykerb, designed to treat adjuvant breast cancer, missed its primary endpoint in a Phase III trial. 

Puma is also trying to develop a breast cancer drug, PB272, for the treatment of HER2 positive metastatic breast cancer. The company actually reported positive results from its ongoing Phase II clinical trial of its experimental drug to treat breast cancer that has metastasized to the brain, but the GlaxoSmithKline news sent the stock plummeting.

The stock was down 21.14% to $60.27 at 11:22 a.m.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PBYI Price Chart

PBYI Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives